This study is looking at how attention works in people who feel their memory or thinking skills are declining, even if standard tests show they are still normal (Subjective Cognitive Decline or SCD). Researchers want to see if a single dose of mecamylamine (a drug that affects attention) or a placebo (an inactive pill) changes how your brain's attention networks work. They will measure this using an EEG (electroencephalography, which measures brain waves) and attention tests. The study aims to understand if people with more subjective cognitive concerns rely more on their attention networks to stay sharp, and if disrupting this process with mecamylamine has a greater impact on them. You may be able to join if you are 55 or older, a non-smoker, and have good scores on cognitive tests like the MoCA. The study plans to enroll 80 participants.

Study design

This is an interventional study with 80 participants. It is double-blinded and randomized, meaning neither you nor the researchers will know if you receive mecamylamine or placebo.

What's involved

You will complete two study visits, which will include cognitive testing and an EEG session. Screening procedures involve medical history review, vital signs, an electrocardiogram, and blood tests.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured approximately 72 hours after the second drug challenge.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.